Efficacy Trial of Oral Tetrahydrocannabinol in Patients With Fibromyalgia
NCT ID: NCT01149018
Last Updated: 2010-06-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
80 participants
INTERVENTIONAL
2010-06-30
2012-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Impact of THC on Pain Modulation in Fibromyalgia
NCT05644054
Biosignature of the Response to Treatment With Cannabis Oil in Individuals With Fibromyalgia
NCT06946940
Cannabidiol for Fibromyalgia (The CANNFIB Trial)
NCT04729179
Psilocybin as a Treatment for Chronic Pain in Smokers
NCT07118332
Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia
NCT00755521
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tetrahydrocannabinol
Tetrahydrocannabinol
Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
Placebo
Placebo
Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tetrahydrocannabinol
Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
Placebo
Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
Patients with following psychiatric disorders:
* Psychosis or history of acute psychosis
* Schizophrenia
* Bipolar disorder Patients smoking marijuana, using hashish or any other form of cannabis. Patients with history of drug abuse or illicit drug use Patients receiving chronic treatment with strong opioids (Morphine, Oxycodone, Fentanyl, Methadone, Hydromorphone, Buprenorphine, Pethidine). Weak opioids as Tramadol or Propoxyphene will be allowed.
Pregnant patients
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hebrew University of Jerusalem
OTHER
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hadassah Medical Organization
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pain Relief Unit, Hadassah Medical Organisation
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Elyad Davidson, MD
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
THC-FMS-HMO-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.